CARA RSI Chart
Last 7 days
4.2%
Last 30 days
2.7%
Last 90 days
19.1%
Trailing 12 Months
-80.5%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 16.9M | 0 | 0 | 0 |
2023 | 43.2M | 27.2M | 21.2M | 21.0M |
2022 | 36.0M | 48.9M | 39.4M | 41.9M |
2021 | 107.1M | 79.1M | 51.0M | 23.0M |
2020 | 23.6M | 24.0M | 27.5M | 135.1M |
2019 | 17.9M | 20.2M | 20.9M | 19.9M |
2018 | 0 | 2.9M | 7.9M | 13.5M |
2017 | 361.0K | 636.0K | 911.0K | 911.0K |
2016 | 0 | 2.6M | 1.3M | 86.0K |
2015 | 3.5M | 3.4M | 4.7M | 3.8M |
2014 | 9.8M | 7.6M | 5.4M | 3.2M |
2013 | 0 | 4.8M | 8.4M | 12.0M |
2012 | 0 | 0 | 0 | 1.2M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 02, 2024 | posner christopher | sold | -2,952 | 0.75 | -3,936 | president and ceo |
Apr 05, 2024 | terrillion scott | sold | -2,284 | 0.83 | -2,753 | sec'y; chief compliance & g.c. |
Apr 05, 2024 | goncalves joana | sold | -2,284 | 0.83 | -2,753 | chief medical officer |
Feb 29, 2024 | terrillion scott | sold | -2,930 | 0.89 | -3,293 | sec'y; chief compliance & g.c. |
Feb 29, 2024 | posner christopher | sold | -5,192 | 0.89 | -5,834 | president and ceo |
Feb 29, 2024 | goncalves joana | sold | -2,930 | 0.89 | -3,293 | chief medical officer |
Feb 08, 2024 | posner christopher | sold | -18,854 | 0.53 | -35,575 | president and ceo |
Feb 01, 2024 | posner christopher | sold | -2,739 | 0.55 | -4,981 | president and ceo |
Feb 01, 2024 | terrillion scott | acquired | - | - | 13,500 | sec'y; chief compliance & g.c. |
Feb 01, 2024 | menzaghi frederique ph.d. | acquired | - | - | 13,500 | chief scientific off,svp-r&d |
Which funds bought or sold CARA recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | B. Riley Wealth Advisors, Inc. | reduced | -9.75 | 47,677 | 93,489 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -31.01 | -887 | 4,833 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | sold off | -100 | -69,385 | - | -% |
May 16, 2024 | COMERICA BANK | unchanged | - | 6.00 | 36.00 | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | added | 41.66 | 255,149 | 602,269 | -% |
May 15, 2024 | JACOBS LEVY EQUITY MANAGEMENT, INC | sold off | -100 | -517,773 | - | -% |
May 15, 2024 | FARALLON CAPITAL MANAGEMENT LLC | unchanged | - | 259,894 | 1,416,190 | 0.01% |
May 15, 2024 | STATE STREET CORP | reduced | -1.76 | 154,176 | 912,688 | -% |
May 15, 2024 | Tudor Investment Corp Et Al | unchanged | - | 15,551 | 84,736 | -% |
May 15, 2024 | Squarepoint Ops LLC | sold off | -100 | -28,669 | - | -% |
Unveiling Cara Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Cara Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Cara Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -28.9% | 2,135,000 | 3,004,000 | 4,866,000 | 6,933,000 | 6,165,000 | 3,261,000 | 10,813,000 | 23,003,000 | 4,790,000 | 821,000 | 20,272,000 | 50,877,667 | 81,483,333 | 112,089,000 | 9,266,000 | 5,634,000 | 8,093,000 | 4,511,000 | 5,785,000 | 5,208,000 | 4,382,000 |
Operating Expenses | -10.7% | 31,801,000 | 35,611,000 | 33,764,000 | 39,273,000 | 33,815,000 | 34,568,000 | 34,658,000 | 27,475,000 | 32,701,000 | 34,343,000 | 21,396,000 | 30,876,000 | 25,496,000 | 33,799,000 | 26,286,000 | 31,518,000 | 38,094,000 | 34,481,000 | 40,218,000 | 29,350,000 | 27,516,000 |
S&GA Expenses | -100.0% | - | 6,588,000 | 6,755,000 | 7,545,000 | 6,891,000 | 6,428,000 | 6,912,000 | 7,570,000 | 9,347,000 | 11,512,000 | 5,882,000 | 5,651,000 | 6,365,000 | 6,659,000 | 5,219,000 | 5,410,000 | 4,558,000 | 4,617,000 | 4,226,000 | 4,994,000 | 3,908,000 |
R&D Expenses | -22.7% | 21,964,000 | 28,415,000 | 25,451,000 | 30,310,000 | 24,334,000 | 26,010,000 | 24,691,000 | 19,905,000 | 21,273,000 | 22,831,000 | 15,514,000 | 25,225,000 | 19,131,000 | 27,140,000 | 21,067,000 | 26,108,000 | 33,536,000 | 29,864,000 | 35,992,000 | 24,356,000 | 23,608,000 |
EBITDA Margin | -23.8% | -5.03 | -4.06 | -4.02 | -3.14 | -1.97 | -2.04 | -2.24 | -1.80 | -2.45 | -3.83 | 0.47 | 0.10 | - | - | - | - | - | - | - | - | - |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -255,000 | -132,000 | -182,000 | -122,000 | -166,000 | -330,000 | -235,000 | -85,000 |
Earnings Before Taxes | - | - | - | - | - | - | - | - | - | - | -33,382,000 | -1,013,000 | -30,745,000 | -23,301,000 | 78,654,000 | -16,641,000 | -25,250,000 | -29,044,000 | -28,777,000 | -33,172,000 | -23,195,000 | -22,045,000 |
EBT Margin | -23.8% | -5.05 | -4.08 | -4.03 | -3.15 | -1.98 | -2.04 | -2.24 | -1.81 | -2.46 | -3.84 | 0.46 | 0.10 | - | - | - | - | - | - | - | - | - |
Net Income | 5.1% | -30,696,000 | -32,337,000 | -28,032,000 | -31,479,000 | -26,665,000 | -30,339,000 | -23,180,000 | -4,206,000 | -27,749,000 | -33,382,000 | -1,013,000 | -30,745,000 | -23,301,000 | 78,909,000 | -16,509,000 | -25,068,000 | -28,922,000 | -28,611,000 | -32,842,000 | -22,960,000 | -21,960,000 |
Net Income Margin | -28.0% | -7.23 | -5.65 | -5.49 | -4.11 | -1.95 | -2.04 | -2.25 | -1.36 | -2.58 | -3.84 | 0.47 | 0.11 | - | - | - | - | - | - | - | - | - |
Free Cashflow | -61.1% | -31,289,000 | -19,422,000 | -19,645,000 | -20,445,000 | -34,618,000 | -23,510,000 | -25,192,000 | -4,503,000 | -25,568,000 | -1,412,000 | -14,283,000 | -21,172,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -28.4% | 90.00 | 126 | 115 | 134 | 153 | 182 | 214 | 227 | 224 | 247 | 225 | 221 | 250 | 271 | 147 | 169 | 196 | 233 | 264 | 150 | 171 |
Current Assets | -30.1% | 81.00 | 116 | 101 | 125 | 143 | 169 | 187 | 176 | 152 | 173 | 171 | 164 | 188 | 195 | 133 | 142 | 133 | 166 | 203 | 125 | 144 |
Cash Equivalents | -6.3% | 48.00 | 52.00 | 63.00 | 58.00 | 47.00 | 64.00 | 43.00 | 47.00 | 22.00 | 14.00 | 23.00 | 23.00 | 23.00 | 32.00 | 76.00 | 57.00 | 17.00 | 19.00 | 35.00 | 19.00 | 15.00 |
Inventory | -2.8% | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | 6.8% | 4.00 | 3.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Liabilities | -12.3% | 60.00 | 69.00 | - | - | - | 23.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Liabilities | -41.0% | 15.00 | 26.00 | 23.00 | 25.00 | 17.00 | 23.00 | 28.00 | 21.00 | 18.00 | 18.00 | 16.00 | 15.00 | 17.00 | 18.00 | 17.00 | 25.00 | 33.00 | 43.00 | 48.00 | 40.00 | 42.00 |
Shareholder's Equity | -47.8% | 30.00 | 57.00 | 86.00 | 109 | 137 | 159 | 185 | 204 | 204 | 228 | 207 | 203 | 230 | 249 | 128 | 141 | 160 | 187 | 212 | 100 | 115 |
Retained Earnings | -4.5% | -715 | -684 | -652 | -624 | -592 | -566 | -535 | -512 | -508 | -480 | -447 | -446 | -415 | -392 | -471 | -454 | -429 | -400 | -372 | -339 | -316 |
Additional Paid-In Capital | 0.5% | 745 | 742 | 738 | 734 | 731 | 727 | 723 | 719 | 714 | 709 | 699 | 650 | 646 | 641 | 599 | 595 | 590 | 587 | 584 | 439 | 431 |
Shares Outstanding | 0.3% | 55.00 | 54.00 | 54.00 | 54.00 | 54.00 | 54.00 | 54.00 | 54.00 | 54.00 | 51.00 | 50.00 | 50.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 131 | - | - | - | 417 | - | - | - | 696 | - | - | - | 726 | - | - | - | 784 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -75.3% | -30,453 | -17,370 | -19,645 | -20,445 | -34,618 | -23,510 | -25,192 | -4,503 | -25,525 | -1,245 | -14,116 | -21,005 | -23,721 | 82,088 | -21,620 | -27,652 | -38,303 | -31,166 | -25,637 | -24,896 | -27,526 |
Share Based Compensation | -7.1% | 3,345 | 3,601 | 3,334 | 3,442 | 3,353 | 3,801 | 3,574 | 4,655 | 5,704 | 8,784 | 4,393 | 3,476 | 4,132 | 4,065 | 3,305 | 4,619 | 2,846 | 3,386 | 2,933 | 4,015 | 2,234 |
Cashflow From Investing | 185.9% | 25,951 | -30,205 | 23,155 | 32,803 | 17,708 | 44,423 | 21,176 | 29,677 | 33,431 | -53,581 | 14,433 | 20,528 | 13,869 | -164,155 | 39,539 | 67,382 | 36,959 | 14,738 | -96,881 | 25,228 | 26,399 |
Cashflow From Financing | -101.9% | -685 | 36,475 | 1,116 | - | 560 | 22.00 | 104 | 182 | 3.00 | 45,288 | 339 | 293 | 688 | 38,469 | 395 | 201 | 75.00 | 28.00 | 138,368 | 3,974 | 234 |
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenue: | ||
Total revenue | $ 2,135 | $ 6,165 |
Operating expenses: | ||
Cost of goods sold | 620 | 2,590 |
Research and development | 21,964 | 24,334 |
General and administrative | 6,816 | 6,891 |
Restructuring | 2,401 | |
Total operating expenses | 31,801 | 33,815 |
Operating loss | (29,666) | (27,650) |
Other income, net | 952 | 985 |
Non-cash interest expense on liability related to sales of future royalties and milestones | (1,982) | |
Net loss | $ (30,696) | $ (26,665) |
Net loss per share: | ||
Basic | $ (0.56) | $ (0.49) |
Diluted | $ (0.56) | $ (0.49) |
Weighted average shares: | ||
Basic | 54,588,090 | 53,872,038 |
Diluted | 54,588,090 | 53,872,038 |
Other comprehensive income, net of tax of $0: | ||
Change in unrealized gains on available-for-sale marketable securities | $ 69 | $ 571 |
Total comprehensive loss | (30,627) | (26,094) |
Collaborative revenue | ||
Revenue: | ||
Total revenue | 788 | 2,750 |
Commercial supply revenue | ||
Revenue: | ||
Total revenue | 640 | 3,191 |
Royalty revenue | ||
Revenue: | ||
Total revenue | 125 | |
Clinical compound revenue | ||
Revenue: | ||
Total revenue | 84 | $ 99 |
Other revenue | ||
Revenue: | ||
Total revenue | $ 623 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 46,996 | $ 51,775 |
Marketable securities | 22,777 | 48,983 |
Accounts receivable, net - related party | 1,718 | 2,765 |
Inventory, net | 2,741 | 2,821 |
Income tax receivable | 697 | 697 |
Other receivables | 506 | 555 |
Prepaid expenses | 5,790 | 8,154 |
Restricted cash | 408 | |
Total current assets | 81,225 | 116,158 |
Operating lease right-of-use assets | 3,826 | 4,864 |
Property and equipment, net | 3,548 | 3,322 |
Restricted cash, non-current | 1,500 | 1,500 |
Total assets | 90,099 | 125,844 |
Current liabilities: | ||
Accounts payable and accrued expenses | 14,875 | 25,592 |
Operating lease liability, current | 220 | |
Total current liabilities | 15,095 | 25,592 |
Liability related to sales of future royalties and milestones, net | 38,376 | 37,079 |
Operating lease liability, non-current | 6,825 | 6,088 |
Total liabilities | 60,296 | 68,759 |
Commitments and contingencies (Note 17) | ||
Stockholders' equity: | ||
Preferred stock; $0.001 par value; 5,000,000 shares authorized at March 31, 2024 and December 31, 2023, zero shares issued and outstanding at March 31, 2024 and December 31, 2023 | ||
Common stock; $0.001 par value; 100,000,000 shares authorized at March 31, 2024 and December 31, 2023, 54,667,079 shares and 54,480,704 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 54 | 54 |
Additional paid-in capital | 745,381 | 742,036 |
Accumulated deficit | (715,441) | (684,745) |
Accumulated other comprehensive loss | (191) | (260) |
Total stockholders' equity | 29,803 | 57,085 |
Total liabilities and stockholders' equity | $ 90,099 | $ 125,844 |